Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.22

AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $46.22.

ANAB has been the subject of a number of recent research reports. Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. BTIG Research initiated coverage on AnaptysBio in a research report on Monday, February 26th. They set a “buy” rating and a $55.00 price target for the company. Piper Sandler initiated coverage on AnaptysBio in a research report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 target price for the company. Finally, SVB Leerink initiated coverage on shares of AnaptysBio in a research note on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price for the company.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the sale, the insider now owns 3,240 shares in the company, valued at $81,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total value of $64,260.00. Following the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the insider now owns 3,240 shares of the company’s stock, valued at $81,000. The disclosure for this sale can be found here. Insiders have sold 153,940 shares of company stock worth $3,513,773 in the last ninety days. 35.50% of the stock is owned by insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio during the 1st quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 2,390 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of AnaptysBio by 134.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,381 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of AnaptysBio during the 4th quarter worth $119,000. Finally, SG Americas Securities LLC purchased a new position in AnaptysBio in the fourth quarter valued at $126,000.

AnaptysBio Trading Up 0.9 %

Shares of AnaptysBio stock opened at $26.58 on Wednesday. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $27.50. The firm’s 50 day simple moving average is $22.93 and its two-hundred day simple moving average is $20.78. The firm has a market capitalization of $726.17 million, a price-to-earnings ratio of -4.37 and a beta of -0.32.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. On average, sell-side analysts predict that AnaptysBio will post -6.17 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.